The involvement of epithelial Fas in a human model of graft versus host disease

Transplantation

Volumn 91, Issue 9, 2011, Pages 946-951

  Ruffin, Nicolas ^a   Ahmed, Shaheda S ^b   Osorio, Lyda M ^a   Wang, Xiao Nong ^b   Jackson, Graham H ^b   Collin, Matthew P ^b   Ekre, Hans Peter ^a   Chiodi, Francesca ^c   Dickinson, Anne M ^b,d  

^a IMED AB   (Sweden)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cutaneous; Fas; GVHD

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FAS ANTIGEN; FAS LIGAND; FLUDARABINE; HLA ANTIGEN; MELPHALAN; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; EXPLANT; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKIN DISEASE; SKIN EPITHELIUM; SKIN GRAFT; UPREGULATION;

ANIMALS; ANTIGENS, CD95; FAS LIGAND PROTEIN; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; SKIN; TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION;

EID: 79955546417     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318212c833     Document Type: Article

References (35)

1. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43: 3.
2. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340.
3. Li-Weber M, Krammer PH. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 2003; 15: 145.
4. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182: 1777.
5. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759.
6. Wehrli P, Viard I, Bullani R, et al. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000; 115: 141.
7. Oishi M, Maeda K, Sugiyama S. Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines. Arch Dermatol Res 1994; 286: 396.
8. Matsue H, Kobayashi H, Hosokawa T, et al. Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN gammatreated cultured keratinocytes. Arch Dermatol Res 1995; 287: 315.
9. Viard-Leveugle I, Bullani RR, Meda P, et al. Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem 2003; 278: 16183.
10. Arnold R, Seifert M, Asadullah K, et al. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: Modulation by cytokines. J Immunol 1999; 162: 7140.
11. Langley RG, Walsh N, Nevill T, et al. Apoptosis is the mode of keratinocyte death in cutaneous graft-versus-host disease. J AmAcad Dermatol 1996; 35(2 part 1): 187.
12. Mori T, Nishimura T, Ikeda Y, et al. Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression. Blood 1998; 92: 101.
13. Baker MB, Altman NH, Podack ER, et al. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183: 2645.
14. Via CS, Nguyen P, Shustov A, et al. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 1996; 157: 5387.
15. Shustov A, Nguyen P, Finkelman F, et al. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: Upregulation of Fas and Fas ligand requires CD8 T cell activation and IFN-gamma production. J Immunol 1998; 161: 2848.
16. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graftversus- host disease pathologies. Blood 1998; 91: 4051.
17. Miwa K, Hashimoto H, Yatomi T, et al. Therapeutic effect of an anti- Fas ligand mAb on lethal graft-versus-host disease. Int Immunol 1999; 11: 925.
18. Wang XN, Collin M, Sviland L, et al. Skin explant model of human graft-versus-host disease: Prediction of clinical outcome and correlation with biological risk factors. Biol Blood Marrow Transplant 2006; 12: 152.
19. Dickinson AM, Sviland L, Carey P, et al. Skin explant culture as a model for cutaneous graft-versus-host disease in humans. Bone Marrow Transplant 1988; 3: 323.
20. Sviland L, Dickinson AM, Carey PJ, et al. An in vitro predictive test for clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1990; 5: 105.
21. Kayaba H, Hirokawa M, Watanabe A, et al. Serum markers of graftversus- host disease after bone marrow transplantation. J Allergy Clin Immunol 2000; 106(1 part 2): S40.
22. Liem LM, van Lopik T, van Nieuwenhuijze AE, et al. Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections. Blood 1998; 91: 1464.
23. Deschaumes C, Verneuil L, Ertault-Daneshpouy M, et al. CD95 liganddependant endothelial cell death initiates oral mucosa damage in a murine model of acute graft versus host disease. Lab Invest 2007; 87: 417.
24. van den Brink MR, Moore E, Horndasch KJ, et al. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease. Transplantation 2000; 70: 184.
25. van Den Brink MR, Moore E, Horndasch KJ, et al. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. J Immunol 2000; 164: 469.
26. Na IK, Lu SX, Yim NL, et al. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. J Clin Invest 2010; 120: 343.
27. Socie G, Mary JY, Lemann M, et al. Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood 2004; 103: 50.
28. Dickinson AM, Sviland L, Dunn J, et al. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro human skin explant model. Bone Marrow Transplant 1991; 7: 209.
29. Jarvis M, Schulz U, Dickinson AM, et al. The detection of apoptosis in a human in vitro skin explant assay for graft versus host reactions. J Clin Pathol 2002; 55: 127.
30. Graubert TA, Russell JH, Ley TJ. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood 1996; 87: 1232.
31. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661.
32. Naumnik W, Izycki T, Ossolinska M, et al. Serum levels of sFas and sFasL during chemotherapy of lung cancer. Exp Oncol 2007; 29: 132.
33. French LE, Tschopp J. Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: Potential for therapeutic inhibition. Schweiz Med Wochenschr 2000; 130: 1656.
34. Schmaltz C, Alpdogan O, Horndasch KJ, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versushost disease and graft-versus-leukemia effect. Blood 2001; 97: 2886.
35. Tsukada N, Kobata T, Aizawa Y, et al. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999; 93: 2738